Cargando…

Improving patient pathways for systemic lupus erythematosus: a multistakeholder pathway optimisation study

OBJECTIVE: Among the most significant challenges in SLE are the excessive diagnosis delay and the lack of coordinated care. The aim of the study was to investigate patient pathways in SLE in order to improve clinical and organisational challenges in the management of those with suspected and confirm...

Descripción completa

Detalles Bibliográficos
Autores principales: Schlencker, Aurelien, Messer, Laurent, Ardizzone, Marc, Blaison, Gilles, Hinschberger, Olivier, Dahan, Etienne, Sordet, Christelle, Walther, Julia, Dory, Anne, Gonzalez, Maria, Kleinlogel, Stéphanie, Bramont-Nachman, Aurélia, Barrand, Lionel, Payen-Revol, Isabelle, Sibilia, Jean, Martin, Thierry, Arnaud, Laurent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109107/
https://www.ncbi.nlm.nih.gov/pubmed/35568439
http://dx.doi.org/10.1136/lupus-2022-000700
_version_ 1784708840552398848
author Schlencker, Aurelien
Messer, Laurent
Ardizzone, Marc
Blaison, Gilles
Hinschberger, Olivier
Dahan, Etienne
Sordet, Christelle
Walther, Julia
Dory, Anne
Gonzalez, Maria
Kleinlogel, Stéphanie
Bramont-Nachman, Aurélia
Barrand, Lionel
Payen-Revol, Isabelle
Sibilia, Jean
Martin, Thierry
Arnaud, Laurent
author_facet Schlencker, Aurelien
Messer, Laurent
Ardizzone, Marc
Blaison, Gilles
Hinschberger, Olivier
Dahan, Etienne
Sordet, Christelle
Walther, Julia
Dory, Anne
Gonzalez, Maria
Kleinlogel, Stéphanie
Bramont-Nachman, Aurélia
Barrand, Lionel
Payen-Revol, Isabelle
Sibilia, Jean
Martin, Thierry
Arnaud, Laurent
author_sort Schlencker, Aurelien
collection PubMed
description OBJECTIVE: Among the most significant challenges in SLE are the excessive diagnosis delay and the lack of coordinated care. The aim of the study was to investigate patient pathways in SLE in order to improve clinical and organisational challenges in the management of those with suspected and confirmed SLE. METHODS: We conducted a cross-sectional study of patients with SLE, healthcare providers and other representative stakeholders. Focus groups were conducted, and based on the collected data the most impactful disruption points in SLE patient pathways were identified. A novel framework to improve individual patient pathways in SLE was developed, discussed and validated during a consensus meeting with representative stakeholders. RESULTS: Six thematic clusters regarding disruption in optimal patient pathways in SLE were identified: appropriate and timely referral strategy for SLE diagnosis; the need for a dedicated consultation during which the diagnosis of SLE would be announced, and following which clarifications and psychological support offered; individualised patient pathways with coordinated care based on organ involvement, disease severity and patient preference; improved therapeutic patient education; prevention of complications such as infections, osteoporosis and cancer; and additional patient support. During the consensus meeting, the broader panel of stakeholders achieved consensus on these attributes and a framework for optimising SLE patient pathways was developed. CONCLUSIONS: We have identified significant disruption points and developed a novel conceptual framework to improve individual patient pathways in SLE. These data may be of valuable interest to patients with SLE, their physicians, health organisations as well as policy makers.
format Online
Article
Text
id pubmed-9109107
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-91091072022-05-27 Improving patient pathways for systemic lupus erythematosus: a multistakeholder pathway optimisation study Schlencker, Aurelien Messer, Laurent Ardizzone, Marc Blaison, Gilles Hinschberger, Olivier Dahan, Etienne Sordet, Christelle Walther, Julia Dory, Anne Gonzalez, Maria Kleinlogel, Stéphanie Bramont-Nachman, Aurélia Barrand, Lionel Payen-Revol, Isabelle Sibilia, Jean Martin, Thierry Arnaud, Laurent Lupus Sci Med Epidemiology and Outcomes OBJECTIVE: Among the most significant challenges in SLE are the excessive diagnosis delay and the lack of coordinated care. The aim of the study was to investigate patient pathways in SLE in order to improve clinical and organisational challenges in the management of those with suspected and confirmed SLE. METHODS: We conducted a cross-sectional study of patients with SLE, healthcare providers and other representative stakeholders. Focus groups were conducted, and based on the collected data the most impactful disruption points in SLE patient pathways were identified. A novel framework to improve individual patient pathways in SLE was developed, discussed and validated during a consensus meeting with representative stakeholders. RESULTS: Six thematic clusters regarding disruption in optimal patient pathways in SLE were identified: appropriate and timely referral strategy for SLE diagnosis; the need for a dedicated consultation during which the diagnosis of SLE would be announced, and following which clarifications and psychological support offered; individualised patient pathways with coordinated care based on organ involvement, disease severity and patient preference; improved therapeutic patient education; prevention of complications such as infections, osteoporosis and cancer; and additional patient support. During the consensus meeting, the broader panel of stakeholders achieved consensus on these attributes and a framework for optimising SLE patient pathways was developed. CONCLUSIONS: We have identified significant disruption points and developed a novel conceptual framework to improve individual patient pathways in SLE. These data may be of valuable interest to patients with SLE, their physicians, health organisations as well as policy makers. BMJ Publishing Group 2022-05-12 /pmc/articles/PMC9109107/ /pubmed/35568439 http://dx.doi.org/10.1136/lupus-2022-000700 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Epidemiology and Outcomes
Schlencker, Aurelien
Messer, Laurent
Ardizzone, Marc
Blaison, Gilles
Hinschberger, Olivier
Dahan, Etienne
Sordet, Christelle
Walther, Julia
Dory, Anne
Gonzalez, Maria
Kleinlogel, Stéphanie
Bramont-Nachman, Aurélia
Barrand, Lionel
Payen-Revol, Isabelle
Sibilia, Jean
Martin, Thierry
Arnaud, Laurent
Improving patient pathways for systemic lupus erythematosus: a multistakeholder pathway optimisation study
title Improving patient pathways for systemic lupus erythematosus: a multistakeholder pathway optimisation study
title_full Improving patient pathways for systemic lupus erythematosus: a multistakeholder pathway optimisation study
title_fullStr Improving patient pathways for systemic lupus erythematosus: a multistakeholder pathway optimisation study
title_full_unstemmed Improving patient pathways for systemic lupus erythematosus: a multistakeholder pathway optimisation study
title_short Improving patient pathways for systemic lupus erythematosus: a multistakeholder pathway optimisation study
title_sort improving patient pathways for systemic lupus erythematosus: a multistakeholder pathway optimisation study
topic Epidemiology and Outcomes
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109107/
https://www.ncbi.nlm.nih.gov/pubmed/35568439
http://dx.doi.org/10.1136/lupus-2022-000700
work_keys_str_mv AT schlenckeraurelien improvingpatientpathwaysforsystemiclupuserythematosusamultistakeholderpathwayoptimisationstudy
AT messerlaurent improvingpatientpathwaysforsystemiclupuserythematosusamultistakeholderpathwayoptimisationstudy
AT ardizzonemarc improvingpatientpathwaysforsystemiclupuserythematosusamultistakeholderpathwayoptimisationstudy
AT blaisongilles improvingpatientpathwaysforsystemiclupuserythematosusamultistakeholderpathwayoptimisationstudy
AT hinschbergerolivier improvingpatientpathwaysforsystemiclupuserythematosusamultistakeholderpathwayoptimisationstudy
AT dahanetienne improvingpatientpathwaysforsystemiclupuserythematosusamultistakeholderpathwayoptimisationstudy
AT sordetchristelle improvingpatientpathwaysforsystemiclupuserythematosusamultistakeholderpathwayoptimisationstudy
AT waltherjulia improvingpatientpathwaysforsystemiclupuserythematosusamultistakeholderpathwayoptimisationstudy
AT doryanne improvingpatientpathwaysforsystemiclupuserythematosusamultistakeholderpathwayoptimisationstudy
AT gonzalezmaria improvingpatientpathwaysforsystemiclupuserythematosusamultistakeholderpathwayoptimisationstudy
AT kleinlogelstephanie improvingpatientpathwaysforsystemiclupuserythematosusamultistakeholderpathwayoptimisationstudy
AT bramontnachmanaurelia improvingpatientpathwaysforsystemiclupuserythematosusamultistakeholderpathwayoptimisationstudy
AT barrandlionel improvingpatientpathwaysforsystemiclupuserythematosusamultistakeholderpathwayoptimisationstudy
AT payenrevolisabelle improvingpatientpathwaysforsystemiclupuserythematosusamultistakeholderpathwayoptimisationstudy
AT sibiliajean improvingpatientpathwaysforsystemiclupuserythematosusamultistakeholderpathwayoptimisationstudy
AT martinthierry improvingpatientpathwaysforsystemiclupuserythematosusamultistakeholderpathwayoptimisationstudy
AT arnaudlaurent improvingpatientpathwaysforsystemiclupuserythematosusamultistakeholderpathwayoptimisationstudy